Fig. 3From: Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancerPrognostic role of MET and p-MET in cetuximab-treated HNSCC patients. a Progression-free survival (PFS) for MET. b Overall survival (OS) for MET. c PFS for p-MET. d OS for p-MET. In light gray line, patients with MET overexpression; in black line, patients without MET overexpressionBack to article page